Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETONNASDAQ:FATENASDAQ:OPTNASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$18.78-0.6%$15.81$3.18▼$21.48$503.59M1.22297,202 shs305,054 shsFATEFate Therapeutics$1.30+7.0%$1.07$0.66▼$5.92$148.41M2.322.21 million shs1.48 million shsOPTOpthea$3.41$3.41$1.79▼$6.30$524.84M1.1226,856 shsN/AVALNValneva$6.37-0.5%$6.56$3.62▼$9.50$532.34M1.8542,452 shs3,814 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals0.00%-4.59%+9.00%+25.75%+432.39%FATEFate Therapeutics0.00%+6.47%-5.73%+19.90%-66.44%OPTOpthea0.00%0.00%0.00%-33.27%+20.07%VALNValneva0.00%+1.62%-4.41%-7.92%-30.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETONEton Pharmaceuticals3.2565 of 5 stars3.55.00.00.03.90.80.6FATEFate Therapeutics4.2395 of 5 stars4.12.00.04.72.11.70.6OPTOpthea0.6665 of 5 stars2.10.00.00.01.30.80.6VALNValneva2.2772 of 5 stars3.55.00.00.01.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 3.00Buy$29.6757.97% UpsideFATEFate Therapeutics 2.22Hold$4.14219.91% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideVALNValneva 3.00Buy$15.50143.52% UpsideCurrent Analyst Ratings BreakdownLatest FATE, ETON, OPT, and VALN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $35.005/16/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $26.005/14/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.005/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/15/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/9/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/31/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$48.33M10.42$0.00 per share4,502.79$0.60 per share31.30FATEFate Therapeutics$13.34M11.13N/AN/A$3.74 per share0.35OPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09VALNValneva$186.06M2.86N/AN/A$2.00 per share3.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$940K-$0.18N/A37.56N/A-15.81%-36.29%-16.84%8/14/2025 (Estimated)FATEFate Therapeutics-$160.93M-$1.49N/AN/AN/A-1,325.43%-45.88%-33.95%8/12/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/AVALNValneva-$109.78M-$1.19N/AN/AN/A-4.35%-3.93%-1.42%8/12/2025 (Estimated)Latest FATE, ETON, OPT, and VALN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ETONEton Pharmaceuticals$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million5/7/2025Q1 2025VALNValneva-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million3/20/2025Q4 2024VALNValneva-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 million3/18/2025Q4 2024ETONEton Pharmaceuticals-$0.02-$0.02N/A-$0.02$10.53 million$11.65 million3/5/2025Q4 2024FATEFate Therapeutics-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton PharmaceuticalsN/A1.511.41FATEFate TherapeuticsN/A8.298.29OPTOptheaN/A2.942.94VALNValneva0.702.782.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%FATEFate Therapeutics97.54%OPTOpthea55.95%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals16.03%FATEFate Therapeutics5.51%OPTOpthea3.20%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2026.82 million22.17 millionOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableOPTOpthea8153.91 million148.98 millionNot OptionableVALNValneva70083.64 million69.15 millionNot OptionableFATE, ETON, OPT, and VALN HeadlinesRecent News About These CompaniesValneva SE (NASDAQ:VALN) Sees Large Decrease in Short InterestJune 2 at 10:13 AM | marketbeat.comValneva to Participate at U.S. and European Investor Conferences in JuneMay 26, 2025 | globenewswire.comUS CDC accepts recommendations for chikungunya vaccinesMay 21, 2025 | msn.comLondon man among thousands who've rolled up their sleeves to trial Lyme disease vaccineMay 19, 2025 | cbc.caUS Advises Older Travelers to Avoid Chikungunya VaccineMay 16, 2025 | infectiousdiseaseadvisor.comFDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for SeniorsMay 15, 2025 | pharmexec.comFDA, CDC recommend pause in Valneva chikungunya vaccine for older adultsMay 14, 2025 | cidrap.umn.eduU.S. Advises Older Travelers to Avoid Chikungunya VaccineMay 13, 2025 | usnews.comFDA warns seniors to avoid this vaccine after deadly complicationsMay 13, 2025 | msn.com2VALN : US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For...May 13, 2025 | benzinga.comCOVID-19 fueled increase in hospital-onset MRSA, study findsMay 12, 2025 | cidrap.umn.eduFDA, EU Flag Safety Issues With Valneva’s Chikungunya VaccineMay 12, 2025 | biospace.comFDA follows EMA in limiting use of Valneva shotMay 12, 2025 | biopharmadive.comWhat Is the Chikungunya Vaccine? CDC Issues Notice to Older TravelersMay 12, 2025 | msn.comUS health officials advise older travelers not to get a chikungunya vaccineMay 12, 2025 | apnews.comValneva’s chikungunya vaccine use halted in older adults amid safety concernsMay 12, 2025 | finance.yahoo.comValneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United StatesMay 12, 2025 | globenewswire.comU.S. recommends a pause in Valneva chikungunya vaccine for those over 60May 10, 2025 | msn.comEli Lilly extends Purdue alliance; EMA investigates Valneva shotMay 10, 2025 | finance.yahoo.comValneva SE 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comValneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...May 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Here's Why Call Option Traders Love Dutch Bros Stock By Gabriel Osorio-Mazilli | May 12, 2025View Here's Why Call Option Traders Love Dutch Bros Stock Lyft: Profitability Milestone and Buyback Fuel Investor OptimismBy Jeffrey Neal Johnson | May 13, 2025View Lyft: Profitability Milestone and Buyback Fuel Investor OptimismFATE, ETON, OPT, and VALN Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$18.78 -0.11 (-0.58%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Fate Therapeutics NASDAQ:FATE$1.30 +0.09 (+7.02%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 05/30/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Valneva NASDAQ:VALN$6.36 -0.04 (-0.55%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
